ReviewThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2026
Artificial intelligence in heart failure.
Review in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHeart failure (HF) affects millions of individuals worldwide and shows an increasing trend, constituting a serious public health issue. Considerable attention has been paid to the screening, diagnosis, risk prediction, treatment, and prognosis of HF. Although many guidelines for the management of HF have been proposed in recent years, the efficacy of evidence-based treatments seems to vary among patients. Therefore, the era of "one-size-fits-all" approaches is drawing to a close, and the concepts of precision medicine and individualized medicine are gradually taking root. Artificial intelligence (AI) is an emerging discipline in the rapidly growing field of computer science. It has now become deeply involved in all aspects of cardiovascular disease research, with particular relevance to HF, though its translation into clinical practice is yet to be fully realized. Although the use of AI in cardiovascular disease (CVD) and HF patient care, as well as cardiac resynchronization therapy (CRT), has been extensively discussed, a discussion from the standpoint of all aspects of HF clinical process is lacking. MAIN BODY: This review provides a comprehensive overview of the use of AI in HF in specific scenarios, including patient diagnosis, subtyping, prognostic assessment, pre- and post-treatment evaluation, and telecare. It also presents the prospects and challenges for the development of AI in the field of HF, with the expectation that a mature AI diagnosis and treatment system adapted to clinical practice will be developed in the future through in-depth research and validation.
conclusionsThis review summarizes the application of AI in various links of HF management from diagnosis to telecare, and analyzes its current application limitations, existing challenges and future research directions, aiming to provide a reference for the subsequent clinical transformation and research optimization of AI in the HF field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.